Compare Quest Diagnostics Inc (DGX) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fox Corp Class A — how do they compare? Quest Diagnostics Inc trades at $236.62 (market cap $26.21B), while Fox Corp Class A trades at $61.69 (market cap $24.58B). The key difference: Quest Diagnostics Inc and Fox Corp Class A are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | FOXA | |
|---|---|---|
Market Cap | $26.21B | $24.58B |
Sector | Health | Media |
52-Week High | $238.50 | $76.11 |
52-Week Low | $173.49 | $48.79 |
Enterprise Value | $31.97B | $27.94B |
Dividend Yield | 1.45% | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
FOXA stock trades at $61.69, down 2.74% today, amid a bullish technical setup with strong support at $60. The company reported robust Q4 2026 results, beating earnings estimates with $1.79 EPS versus $1.44 expected, driven by World Cup advertising and Tubi streaming growth. Revenue rose 28% year-over-year to $4.21 billion in the quarter. Analyst sentiment is evenly split between Buy and Hold ratings, with a consensus price target of $65.33.
The outlook remains positive given strong ad demand and digital momentum, but risks include higher sports costs and reliance on major events. Earnings growth and streaming execution are key catalysts for further upside, though valuation multiples appear reasonable with a P/E of 16.18.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
